Memorial Sloan Kettering Cancer Center | Strategic Alliance Partners

Bijal Shah, MD, MS, and Jae Park, MD, discuss how inotuzumab exposure may influence response to obe-cel in ALL.

Bijal Shah, MD, MS, and Jae Park, MD, predictors of sustained remission with obe-cel in acute lymphoblastic leukemia.

Bijal Shah, MD, MS, and Jae Park, MD, discuss an age-based analysis of outcomes with obe-cel in acute lymphoblastic leukemia.

Bijal Shah, MD, MS, and Jae Park, MD, discuss how the integration of obe-cel has affected the acute lymphoblastic treatment paradigm.

Yelena Y. Janjigian, MD, discussed results from the MATTERHORN study of durvalumab plus FLOT in resectable gastric/gastroesophageal junction cancer.

Kate Gasparini, PharmD, BCOP, BCPPS, discusses issues with administering oral agents in pediatric patients with cancer or patients with dysphagia.

Kate Gasparini, PharmD, BCOP, BCPPS, discusses the oral formulation of imatinib for pediatric and adult patients with leukemias and other malignancies.

The FDA has granted accelerated approval to avutometinib/defactinib for KRAS-mutant recurrent low-grade serous ovarian cancer.

Tarlatamab improved overall survival and progression-free survival in the second-line treatment of small cell lung cancer.

The addition of durvalumab to perioperative FLOT improved event-free survival in resectable gastric/GEJ adenocarcinoma.

Here is your snapshot of all therapeutic options that were approved by the FDA in May 2025 spanning tumor types.

The addition of pelabresib to ruxolitinib generated a significant improvement in spleen response in patients with JAK inhibitor–naive myelofibrosis.

Dr. Kathryn C. Arbour presents preliminary findings from a Phase 1 study showing that zoldonrasib, a selective RAS(ON) G12D inhibitor, demonstrates encouraging antitumor activity and a manageable safety profile in patients with previously treated KRAS G12D–mutant non–small cell lung cancer.

Yelena Y. Janjigian, MD, discusses the safety of nivolumab plus chemotherapy for the first-line treatment of patients with gastric/GEJ/esophageal cancer.

Dr Mauro discusses ways that the newest formulation of nilotinib for Ph-positive CML addresses treatment adherence issues by reducing the need for fasting.

Michael A. Postow, MD, and Chenyang Zhan, MD, PhD, discuss ongoing research to watch in advanced melanoma.

Michael A. Postow, MD, and Chenyang Zhan, MD, PhD, discuss where RP1 plus nivolumab could fit in the advanced melanoma treatment paradigm.

Michael A. Postow, MD, and Chenyang Zhan, MD, PhD, break down data from the IGNYTE trial of RP1 plus nivolumab in advanced melanoma after PD-1 inhibition.

Michael A. Postow, MD, and Chenyang Zhan, MD, PhD, dive into research behind oncolytic viruses in advanced melanoma.

Michael A. Postow, MD, and Chenyang Zhan, MD, PhD, discuss the role of interventional radiologists in melanoma management.

Michael A. Postow, MD, and Chenyang Zhan, MD, PhD, discuss unmet needs in advanced melanoma after checkpoint inhibition.

The top 5 OncLive videos of the week cover insights in myelodysplastic syndrome, lung cancer, hepatocellular carcinoma, colorectal cancer, and ovarian cancer.

Dr Arbour discusses the mechanisms of action of zoldonrasib and daraxonrasib and shares early data with these agents in RAS-mutant NSCLC.

James J. Harding, MD, discusses efficacy data with nivolumab plus ipilimumab that led to this regimen’s FDA approval for unresectable or metastatic hepatocellular carcinoma

Alexis Chidi, MD, PhD, MSPH, emphasizes the importance of having more available targeted therapies and explains NSCLC screening eligibility criteria.

Alexis Chidi, MD, PhD, MSPH, details the evolution of surgical approaches in early-stage lung cancer, including wedge resections and segmentectomies.

Catherine Thieblemont, MD, PhD, and Paola Ghione, MD, MSEpi, discuss insights into marginal zone lymphoma.

Eighty percent of patients with early-stage dMMR solid tumors given neoadjuvant dostarlimab underwent nonoperative management of their disease.

Experts from across oncology specialties highlight research being presented at the 2025 AACR Annual Meeting.

Raajit Rampal, MD, discusses treatment decision-making factors, such as JAK inhibitor efficacy and signs of treatment failure, for myelofibrosis.